No Data
No Data
Henan Lingrui Pharmaceutical Plans Further 50-Million-Yuan Investment in Xiamen Jinyixing Fund; Shares Up 5%
Zhongtai Securities: Short-term performance pressure in the traditional Chinese medicine sector, with main focus on improving quality and efficiency.
Against the backdrop of high base numbers in H1 2023, the traditional chinese medicine sector's performance is under short-term pressure. With the fading of the base effect and the arrival of the peak season in autumn and winter, the sector's performance is expected to gradually improve.
Henan Lingrui Pharmaceutical (600285.SH): Intends to invest an additional 50 million yuan to subscribe for more shares of Jinbaoxuan.
Lingrui Pharmaceutical (600285.SH) announced on September 13th that since its establishment, Jingyexing has maintained a good business development trend. In order to fully leverage the advantages of all parties, further expand the company's investment channels, and optimize the company's investment and business layout in technology innovation and domestic demand market through professional investment institutions, according to the company's strategic planning, the company intends to act as a limited partner of Jingyexing and add RMB 50 million of its own funds to subscribe for additional Jingyexing shares. After the additional investment, the company's cumulative subscribed amount in Jingyexing reaches RMB 150 million, accounting for 16.6667% of the total subscribed capital of Jingyexing.
Express News | Tianfeng Securities: Focus on the three investment themes of the pharmaceutical industry.
Express News | Retirement funds appeared in the top ten circulating shareholders of 16 stocks in the second quarter.
Express News | Retirement funds appeared in the top ten shareholders for a total of 13 stocks in the second quarter.
No Data
No Data